Evidence map›Paper›PMID 38844698›Full record

ReviewEJNMMI radiopharmacy and chemistry2024

Trans-cyclooctene-a Swiss army knife for bioorthogonal chemistry: exploring the synthesis, reactivity, and applications in biomedical breakthroughs.

Karuna Adhikari, Maarten Vanermen, Gustavo Da Silva, Tim Van den Wyngaert, Koen Augustyns, Filipe Elvas

Abstract readReview
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Head-to-Head Comparison of theMolecular pharmaceutics · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karuna AdhikariLaboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium.
Maarten VanermenLaboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium.
Gustavo Da SilvaMolecular Imaging and Radiology, University of Antwerp, Antwerp, Belgium.
Tim Van den WyngaertMolecular Imaging and Radiology, University of Antwerp, Antwerp, Belgium.
Koen AugustynsLaboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium. Koen.Augustyns@uantwerpen.be.
Filipe ElvasMolecular Imaging and Radiology, University of Antwerp, Antwerp, Belgium. Filipe.Elvas@uantwerpen.be.ORCID http://orcid.org/0000-0001-9790-3369

Funding

BOF-UA 541200003FWO 1156820NFWO 1156822N
6 · The paper itself

Abstract

backgroundTrans-cyclooctenes (TCOs) are highly strained alkenes with remarkable reactivity towards tetrazines (Tzs) in inverse electron-demand Diels-Alder reactions. Since their discovery as bioorthogonal reaction partners, novel TCO derivatives have been developed to improve their reactivity, stability, and hydrophilicity, thus expanding their utility in diverse applications. MAIN BODY: TCOs have garnered significant interest for their applications in biomedical settings. In chemical biology, TCOs serve as tools for bioconjugation, enabling the precise labeling and manipulation of biomolecules. Moreover, their role in nuclear medicine is substantial, with TCOs employed in the radiolabeling of peptides and other biomolecules. This has led to their utilization in pretargeted nuclear imaging and therapy, where they function as both bioorthogonal tags and radiotracers, facilitating targeted disease diagnosis and treatment. Beyond these applications, TCOs have been used in targeted cancer therapy through a "click-to-release" approach, in which they act as key components to selectively deliver therapeutic agents to cancer cells, thereby enhancing treatment efficacy while minimizing off-target effects. However, the search for a suitable TCO scaffold with an appropriate balance between stability and reactivity remains a challenge.

conclusionsThis review paper provides a comprehensive overview of the current state of knowledge regarding the synthesis of TCOs, and its challenges, and their development throughout the years. We describe their wide ranging applications as radiolabeled prosthetic groups for radiolabeling, as bioorthogonal tags for pretargeted imaging and therapy, and targeted drug delivery, with the aim of showcasing the versatility and potential of TCOs as valuable tools in advancing biomedical research and applications.

Indexed as

Bioorthogonal chemistryIn vivo ligationPretargeted imaging and therapyTrans-cyclooctene

Identifiers

PMID38844698
PMCPMC11156836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.